AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT

Teichos Laboratories, Llc, Indianapolis IN

Investigators

Abstract

The project will optimize a novel adjuvant formulation composed of alum and TL-001, a unique totally synthetic peptidoglycan (sPGN) TLR2 agonist, to improve performance of a registered DTaP subunit vaccine. Preliminary results with TL-001 strongly suggest potential as a non-toxic, single agent vaccine adjuvant. TL-001 and a phosphonylated analogue (pTL-001) will be prepared and their respective affinities for aluminum hydroxide adjuvant (AH) will be compared. Proof-of-concept studies will determine if pTL-001, the novel, soluble, immune response amplifier, combined with alum, enhances the magnitude and quality of humoral and cellular responses compared to the registered vaccine. The project will scale production of TL-001 and pTL-001 for characterization of dose-related induction.